Abstract
BackgroundGeneric drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir.MethodsBetween February and June 2017, switch from Triumeq® to a generic pharmaceutical specialty co-formulated tablet (abacavir + lamivudine) plus Tivicay® was made. Demographic, viroimmunological characteristics and the Charlson index were collected. Six months after switching, efficacy and safety were evaluated.ResultsSwitch was made in 93 patients, with a mean age of 47 years, after six months there were five patients (5.4%) with viral loads between 50 and 400 copies, no patient had viral loads of greater amount. There were 2 interruptions due to toxicity (2.15%), in relation to symptoms of the central nervous system. There were no differences in the amount of years with HAART, nor in the previous months with the STR regimen based on abacavir + lamivudine + dolutegravir, nor in the Charlson index. The effective saving in 2017 derived from the change in these 93 patients was € 125.512.ConclusionsThe change from a regimen of abacavir + lamivudine + dolutegravir seems to be safe and effective at 24 weeks.
Highlights
Generic drugs may help to support antiretroviral treatment
Highly active antiretroviral therapy (HAART) based on the combination of three drugs remains the model of treatment for HIV infection
In the Pharmacy Service, the Pharmacist reinforced the information that the doctor had given to the patient, explaining the change of HAART consisting of the modification of the number of tablets maintaining the same combination of active ingredients
Summary
Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. The emergence of generic drugs in the Spanish market has posed a scenario in which it is possible to save costs at the expense of breaking STR regimes. In this context, the generic of abacavir + Lamivudine (ABC + 3TC) was commercialized in mid-2016. The generic of abacavir + Lamivudine (ABC + 3TC) was commercialized in mid-2016 This allowed to have a regimen with ABC 600 mg + LMV 300 mg and dolutegravir (DTG) 50 mg more cost effective than ABC + 3TC + DTG in STR, which led to the possibility of modifying the treatment of patients undergoing treatment with the STR of ABC + 3TC + DTG to the combination of a generic pill of ABC + 3TC with a pill of dolutegravir. We report in this study the early experience (at 24 weeks) of the STR break of ABC + 3TC + DTG and its replacement by a two-tablet
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
